U.S. Markets open in 8 hrs 14 mins

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

Zacks Equity Research

Pfizer, Inc.’s PFE rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate (MTX) or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

Xeljanz (5 mg twice daily), a JAK inhibitor, is presently approved in the U.S. as a second-line treatment for moderate-to-severely active RA in patients who have had an inadequate response to or cannot tolerate methotrexate. In Feb 2016, the FDA approved a once-daily extended-release (XR) formulation of Xeljanz (11 mg) tablets.

Pfizer’s shares are up 6.6% so far this year, almost in line with the Zacks classified Large-Cap Pharma industry’s return of 6.5%.

Xeljanz did well last year with sales of $927 million, up 77% from prior year. Xeljanz (5 mg, twice daily) is under regulatory review in the EU.

Last month, Pfizer announced top-line results from a head-to-head study comparing Xeljanz with AbbVie, Inc.’s ABBV Humira.

The phase IIIb/IV ORAL Strategy study (n=1,152) compared Xeljanz (5 mg twice daily) as a monotherapy or in combination with methotrexate (MTX) versus Humira plus MTX. The study demonstrated non-inferiority of Xeljanz plus MTX versus Humira plus MTX, thereby meeting the primary endpoint. However, Xeljanz monotherapy did not demonstrate non-inferiority versus Humira plus MTX, thereby failing to meet the primary endpoint.

Xeljanz is also being studied for the treatment of active psoriatic arthritis (PsA) and ulcerative colitis. Label and geographical expansion will boost the drug’s commercial potential significantly.

Blockbuster drugs currently approved to treat RA include Johnson & Johnson’s JNJ Remicade and Amgen, Inc.’s AMGN Enbrel that Pfizer markets outside the U.S. and Canada.

Pfizer carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

More Stock News: 8 Companies Verge on Apple-Like Run                                               

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

 A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.